NGM Biopharmaceuticals Inc at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript

Apr 28, 2022 / 02:30PM GMT
Mayank Mamtani - B. Riley Securities - Analyst

Hi, good morning. This is Mayank Mamtani, senior biotech analyst at B. Riley. I'm delighted to take off our next fireside chat with NGM Biopharmaceuticals. I'm pleased to have with me David Woodhouse, the CEO; and Siobhan, the CFO.

Questions and Answers:

Mayank Mamtani - B. Riley Securities - Analyst

Maybe, David, if you could kick us off with providing the overview of your pipeline, very big pipeline, but the focus obviously is on ophthalmology today. And maybe also give us the details of the Merck collaboration you have around that.

David Woodhouse - NGM Biopharmaceuticals, Inc. - CEO

Sure, and thanks for having us today, Mayank. Yeah. Our biologics discovery platform -- so we have quite a broad pipeline. It spans liver, metabolic, oncology, and ophthalmology. We have seven programs, almost all of them in the clinic, or the last of those seven will go into clinic this quarter. But I understand today is on oncology -- or on ophthalmology.

And so our lead
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot